Company intelligence / Profile preview
Swarm Oncology Ltd.
London, Greater London, United Kingdomswarmoncology.bio ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Swarm Oncology is developing novel T cell therapies to overcome limitations of current immunotherapy approaches for solid cancers. Their proprietary platform leverages immune system priming with ex vivo cell processing to generate large numbers of T cells with desired phenotypes to home, infiltrate, and kill cancer cells.
- Therapeutic areas
- Oncology
- Modalities
- T cell therapiescellular immunotherapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Cellex Cell Professionals GmbH (strategic partnership announced February 24, 2025)
Beyond the preview
Go deeper on Swarm Oncology Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Swarm Oncology Ltd..